Single annual injectable treatment for postmenopausal osteoporosis

Expert Opinion on Drug Delivery

Volumn 5, Issue 5, 2008, Pages 583-591

  Chapurlat, Roland D ^a  

^a UNIVERSITÉ DE LYON   (France)

Author keywords

Bisphosphonates; Fracture; Osteoporosis; Zoledronic acid

Indexed keywords

ALENDRONIC ACID; AMINO TERMINAL TELOPEPTIDE; BISPHOSPHONIC ACID DERIVATIVE; CALCITONIN; CALCIUM; CARBOXY TERMINAL TELOPEPTIDE; COLECALCIFEROL; ERGOCALCIFEROL; ESTROGEN; IBANDRONIC ACID; IPRIFLAVONE; MEDROXYPROGESTERONE; PAMIDRONIC ACID; PARATHYROID HORMONE[1-34]; PLACEBO; PRASTERONE; RALOXIFENE; RECLAST; STRONTIUM RANELATE; TAMOXIFEN; TIBOLONE; VITAMIN D; ZOLEDRONIC ACID;

ABDOMINAL PAIN; BODY MASS; BONE BIOPSY; BONE DENSITY; BONE MINERALIZATION; BONE NECROSIS; BONE PAIN; BONE REMODELING; BONE TURNOVER; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; CREATININE BLOOD LEVEL; DIGESTIVE SYSTEM DISEASE; DISEASE SEVERITY; DOSE RESPONSE; DRUG EFFICACY; DRUG FATALITY; DRUG INTERMITTENT THERAPY; DRUG POTENCY; DRUG RESPONSE; DRUG SAFETY; DRUG WITHDRAWAL; DYSPEPSIA; ESOPHAGITIS; ESTROGEN DEFICIENCY; FEVER; FLU LIKE SYNDROME; FRAGILITY FRACTURE; HEART ARRHYTHMIA; HEART ATRIUM FIBRILLATION; HIP FRACTURE; HUMAN; HYPOCALCEMIA; KIDNEY DISEASE; LOADING DRUG DOSE; MYALGIA; NONHUMAN; OSSIFICATION; OSTEOLYSIS; PATIENT COMPLIANCE; POSTMENOPAUSE OSTEOPOROSIS; REVIEW; RISK ASSESSMENT; RISK FACTOR; RISK REDUCTION; SIDE EFFECT; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT;

ANIMALS; BONE DENSITY CONSERVATION AGENTS; CLINICAL TRIALS AS TOPIC; DELAYED-ACTION PREPARATIONS; DIPHOSPHONATES; FRACTURES, BONE; HUMANS; IMIDAZOLES; OSTEOPOROSIS, POSTMENOPAUSAL; RECURRENCE;

EID: 45849104590     PISSN: 17425247     EISSN: None     Source Type: Journal    
DOI: 10.1517/17425247.5.5.583     Document Type: Review

References (51)

1. Melton LJ III. Who has osteoporosis? A conflict between clinical and public health perspectives. J Bone Miner Res 2000;15:2309-14
2. Oden A, Dawson A, Dere W, et al. Lifetime risk of hip fractures is underestimated. Osteoporas Int 1998;8:599-603
3. NIH Consensus Development Panel on osteoporosis prevention, diagnosis and therapy. JAMA 2001;285:785-95
4. Center JR, Nguyen TV, Schneider D, et al. Mortality after all major types of osteoporotic fracture in men and women: an observational study. Lancet 1999;353:878-82
5. Farahmand BY, Michaelsson K, Ahlbom A, et al. Survival after hip fracture. Osteoporos Int 2005;16:1583-90
6. Kado DM, Browner WS, Palermo L, et al. Vertebral fractures and mortality in older women: a prospective study. Arch Int Med 1999;159:1215-20
7. Bonar SK, Tinetti ME, Speechley M, Cooney LM. Factors associated with short- versus long-term skilled nursing facility placement among community-living hip fracture patients. J Am Geriatr Soc 1990;38:1139-44
8. Cummings SR, Nevitt MC, Browner WS, et al. Risk factors for hip fracture in white women. N Engl J Med 1995;332:767-73
9. Kanis JA, Borgstrom F, De Laet C, et al. Assessment of fracture risk. Osteoporos Int 2005;16:581-9
10. Seeman E. Pathogenesis of bone fragility in women and men. Lancet 2002;359:1841-50
11. Riggs LB, Parfitt MA. Drugs used to treat osteoporosis: the critical need for a uniform nomenclature based on their action on bone remodelling. J Bone Miner Res 2005;20:177-84
12. Ettinger B, Black DM, Mitlak BH, et al. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) investigators. JAMA 1999;282:637-45
13. Chestnut CH III, Silverman S, Andriano K, et al. For the PROOF study group. A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: the PROOF Study. Am J Med 2000:109:267-76
14. Cummings SR, Chapurlat RD. What PROOF proves about calcitonin and clinical trials. Am J Med 2000;109:330-1
15. Liberman UA, Weiss SR, Bröll J, et al. Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. N Engl J Med 1995;333:1437-43
16. Black DM, Cummings SR, Karpf DB, et al. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Lancet 1996;348:1535-41
17. Cummings SR, Black DM, Thompson DE, et al. Effect of alendronate on risk of fracture in women with low bone mineral density but without vertebral fractures. JAMA 1998;280:2077-82
18. Harris ST, Watts N, Genant HK, et al. Effects of risedronate treatment on vertebral and non-vertebral fractures in women with postmenopausal osteoporosis. JAMA 1999;282:1344-52
19. Reginster J-Y, Minne HW, Sorensen OH, et al. Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Osteoporos Int 2000;11:83-91
20. Chestnut CH III, Skag A, Christiansen C, et al. Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis. J Bone Miner Res 2004;19:1241-9
21. Boonen S, Laan RF, Barton IP, Watts NB. Effect of osteoporosis treatments on risk of non-vertebral fractures: review and meta-analysis of intention-to-treat studies. Osteoporos Int 2005;16:1291-8
22. Neer RM, Arnaud CD, Zanchetta JR, et al. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 2001;344:1434-41
23. Greenspan SL, Bone HG, Ettinger MP, et al. Effect of recombinant human parathyroid hormone (1-84) on vertebral fracture and bone mineral density in postmenopausal women with osteoporosis: a randomized trial. Ann Intern Med 2007;146:326-39
24. Boonen S, Lips P, Bouillon R, et al. Need for additional calcium to reduce the risk of hip fracture with vitamin D supplementation: evidence from a comparative metaanalysis of randomized controlled trials. J Clin Endocrinol Metab 2007;92:1415-23
25. Meunier PJ, Roux C, Seeman E, et al. The effects of strontium ranelate on the risk of vertebral fracture in women with poatmenopausal osteoporosis. N Engl J Med 2004;350:459-68
26. Reginster JY, Seeman E, De Vernejoul MC, et al. Strontium ranelate reduces the risk a non-vertebral fractures in postmenopausal women with osteoporosis: treatment of peripheral osteoporosis (TROPOS) study. J Clin Endocrinol Metab 2005;90:2816-22
27. DIN-LINK data, CompuFile Ltd; 2003
28. Cro JJ, Ishak KJ, Huybrechts KF, et al. The impact of compliance with osteoporosis therapy on fracture rates in actual practice. Osteoporos Int 2004; 15:1003-8
29. Solomon DH, Avorn J, Katz JN, et al. Compliance with osteoporosis medications. Arch Int Med 2005;165:2414-9
30. McCombs JS. Compliance with drug therapies for the treatment and prevention of osteoporosis. Maturitas 2004;48:271-87
31. Tosteson AN, Grove MR, Hammond CS, et al. Early discontinuation of treatment for osteoporosis. Am J Med 2003;115:209-16
32. Caro JJ, Ishak KJ, Huybrechts KF, et al. The impact of compliance with osteoporosis therapy on fractures rates in actual practice. Osteoporos Int 2004;15:1003-8
33. Recker RR, Gallagher R, McCosbe PE. Effect of dosing frequency on bisphosphonate medication adherence in a large longitudinal cohort of women. Mayo Clin Proc 2005;80:856-61
34. Reginster JY, Adami S, Latakos P, et al. Efficacy and tolerability of once-monthly oral ibandronate in postmenopausal osteoporosis: 2 year results from the MOBILE study. Ann Rheum Dis 2006;65:654-61
35. Harris ST, Blumentals WA, Miller PD. Ibandronate and the risk of non-vertebral and clinical fractures in women with postmenopausal osteoporosis: results of a meta-analysis of Phase III studies. Curr Med Res Opin 2008;24:237-45
36. Pataki A, Muller K, Green JR, et al. Effects of short-term treatment with the bisphosphonates zoledronate and pamidronate on rat bone: a comparative histomorphometric study on the cancellous bone before, during and after treatment. Anat Rec 1997;249:458-68
37. Binkley N, Kimmel D, Bruner J, et al. Zoledronate prevents the development of absolute osteopoenia following ovariectomy in adult rhesus monkeys. J Bone Miner Res 1998;13:1775-82
38. Reid IR, Brown JP, Burkhardt P, et al. Intravenous zoledronic acid in pastmenopausal women with low bone mineral density. N Engl J Med 2002;346:653-61
39. Devogelaer JP, Brown JP, Burckhardt P, et al. Zoledronic acid efficacy and safety over five years in postmenopausal women. Osteoporos Int 2007;18:1211-8
40. Saag K, Lindsay R, Kriegman A, et al. A single zoledronic acid infusion reduces bone resorption markers more rapidly than weekly oral alendronate in postmenopausal women with low bone mineral density. Bone 2007;40:1238-43
41. Black DM, Delmas PD, Eastell R, et al. One-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med 2007;356:1809-22
42. Lyles KW, Colon-Emeric CS, Magaziner JS, et al. Zoledronic acid and clinical fractures and mortality after hip fractures. N Engl J Med 2007;357:1799-809
43. Recker R, Delmas PD, Halse J, et al. The effects of intravenous zoledronic acid once yearly on bone remodelling and bone structure. J Bone Miner Res 2008;23:6-16
44. McClung MR, Geusens P, Miller PD, et al. Effect of risedronate on the risk of hip fracture in elderly women. N Engl J Med 2001;344:333-40
45. Chapurlat RD, Bauer DC, Nevitt M, et al. Incidence and risk factors for a second hip fracture in elderly women. The study of osteoporotic fractures. Osteoporos Int 2003;14:130-6
46. Cummings SR, Schwartz AV, Black DM. Alendronate and atrial fibrillation. N Engl J Med 2007;356:1895-6
47. Karam R, Camm J, McClung M. Yearly zoledronic acid in postmenopausal osteoporosis. N Engl J Med 2007;357:712
48. Sorensen HT, Christensen S, Mehnert F, et al. Use of bisphosphonates and risk of atrial fibrillation and flutter. BMJ 2008 Mar 11 [Epub ahead of print]
49. Poole KE, Kaptoge S, Reeve J. Yearly zoledronic acid in postmenopausal osteoporosis. N Engl J Med 2007;357:711-2
50. McClung M, Recker R, Miller P, et al. Intravenous zoledronic acid 5 mg in the treatment of postmenopausal women with low bone density previously treated with alendronate. Bone 2007;41:122-8
51. Khosla S, Burr D, Cauley J, et al. Bisphosphonate-associated osteonecrosis of the jaw: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res 2007:1479-91